1. Gerlich WH. Medical virology of hepatitis B: How it began and where we are now. Virol J 2013;10: 239.
2. Galibert F, Mandart E, Fitoussi F, et al. Nucleotide sequence of the hepatitis B virüs genome (subtype ayw) cloned in E. coli. Nature 1979; 281: 646–650.
3. Seeger C, Zoulim F, Mason WS. Hepadnavirüses. In: Howley PM, Knipe DM (eds). Fields Virology, 7th ed. Philadelphia: Lippincott Williams & Wilkins Publishers; 2021.
4. Datta S, Chatterjee S, Veer V, Chakravarty R. Molecular biology of the hepatitis B virüs for clinicians. J Clin Exp Hepatol 2012;2(4): 353-365.
5. Tsukuda S, Watashi K. Hepatitis B virüs Biology and life circle. Antiviral Research 2020; 182: 104925
6. Kar A, Samanta A, Mukherjee S, Barik S, Biswas A. The HBV web: An insight into molecular interactomes between the hepatitis B virüs and its host en route to hepatocellular carcinoma. J
Med Virol 2023;95(1):e28436.
7. Diogo DJ, Sarica N, Neuveut C. Early steps of hepatitis B life cycle: From capsid nuclear import to cccDNA formation. Virüses 2021; 13: 757.
8. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virüs. Elife 2012; 1: e00049.
9. Yamada M, Oeda A, Jung J, et al. Hepatitis B virüs envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. J Contr Release 2012;
160: 322–329.
10. Iwamoto M, Saso W, Nishioka K, et al. The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virüs to the endosomal network.
J Biol Chem 2020; 295: 800–807.
11. Rabe B, Vlachou A, Pante N, Helenius A, Kann M. Nuclear import of hepatitis B virüs capsids and release of the viral genome. Proc Natl Acad Sci U S A 2003; 100: 9849–9854.
12. Nevola R, Beccia D, Rosato V, et al. HBV infection and host interactions: The role in viral persistence and oncogenesis. Int J Mol Sci 2023; 24: 7651.
13. Hu JL, Huang AL. Dynamics of hepatitis B virüs covalently closed circular DNA: A mini-review. Microorganisms 2023; 11: 600.
14. Hong X, Kim ES, Guo H. Epigenetic regulation of hepatitis B virüs covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatology 2017; 66:
2066–2077.
15. Tang H, McLachlan A. Transcriptional regulation of hepatitis B virüs by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci U S A 2001; 98: 1841–1846.
16. Lucifora J, Arzberger S, Durantel D, et al. Hepatitis B virüs X protein is essential to initiate and maintain virüs replication after infection. J Hepatol 2011; 55, 996–1003.
17. Sekiba K, Otsuka M, Ohno M, et al. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction. Cell Mol Gastroenterol Hepatol 2019; 7:
297–312.
18. Datta S, Chatterjee S, Veer V, Chakravarty R. Molecular biology of the hepatitis B virüs for clinicans. J Clin Exp Hepatol 2012; 2: 353-365.
19. Chong CK, Cheng CYS, Tsoi SYJ, et al. HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. Sci Rep 2020;
10: 802.
20. Kafeero HM, Ndagire D, Ocama P, et al. Mapping hepatitis B virüs genotypes on the African continent from 1997 to 2021: a systematic review with meta-analysis. Sci Rep. 2023;13(1):5723.
21. Toyé RM, Loureiro CL, Jaspe RC, Zoulim F, Pujol FH, Chemin I. The hepatitis B virüs genotypes E to J: The overlooked genotypes. Microorganisms 2023; 11: 1908.
22. Chih-Lin Lin, Jia-Horng Kao. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol 2017; 31: 249-255.
23. Elizalde MM, Tadey L, Mammana L, Quarleri JF, Campos RH, Flichman DM. Biological characterization of hepatitis B virüs genotypes: Their role in viral replication and antigen expression.
Front Microbiol 2021; 12: 758613.
24. Bozdayı G, Türkyılmaz AR, İdilman R, et al. Complete genome sequence and phylogenetic analysis of hepatitis B virüs isolated from Turkish patients with chronic HBV infection. J Med Virol
2005; 76(4): 476-81.
25. Sant’Anna TB, Araujo NM. Hepatitis B virüs genotype D: An overview of molecular epidemiology, evolutionary history, and clinical characteristics. Microorganisms 2023; 11(5): 1101.
26. Chen J, Li L, Yin Q, Shen T. A review of epidemiology and clinical relevance of hepatitis B virüs genotypes and subtypes. Clin Res Hepatol Gastroenterol 2023; 47(7): 102180.
27. Caligiuri P, Cerruti R, Icardi G, Bruzzone B. Overview of hepatitis B virüs mutations and their implications in the management of infection. World J Gastroenterol 2016; 22(1): 145-54.
28. Lazarevic I. Clinical implications of hepatitis B virüs mutations: Recent advances. World J Gastroenterol 2014; 20:7653–7664.
29. Tong S, Revill P. Overview of viral replication and genetic variability. J Hepatol 2016; 64(1 Suppl): S4-S16.
30. Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut 2015; 64(2): 292-302.
31. Chuang YC, Tsai KN, Ou JJ. Pathogenicity and virulence of Hepatitis B virüs. Virulence 2022; 13(1): 258-296.
32. Lazarevic I, Banko A, Miljanovic D, Cupic M. Immune-escape hepatitis B virüs mutations associated with viral reactivation upon immunosuppression. Virüses 2019; 11: 778.
33. Pacheco SR, Dos Santos MIMA, Stocker A, et al. Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B. Infect Drug Resist 2017; 10:
201-207.
34. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virüs infection. J Hepatol 2017; 67(2): 370-398.
35. Tingting Liu, Qingsong Sun, Jiaqi Gu, Shan Cen, Quan Zhang. Characterization of the tenofovir resistance-associated mutations in the hepatitis B virüs isolates across genotypes A to D.
Antiviral Research 2022; 203: 105348.
36. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virüs infection: Epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-25.
37. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23(1): 39–46.
38. Kosan E, Kocazeybek B, Altunay H, et al. Can the nucleic acid amplification test (NAT) be an alternative to the serologic tests? A prospective study, the results of 18,200 blood donors from
the Turkish Red Crescent. Transfus Apher Sci 2010; 43(3): 269-272.
39. Demirtürk N, Köse A, Ural O, ve ark. Kronik hepatit B infeksiyonunun yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Rapo-
ru-2023 Güncellemesi. Klimik Derg 2023; 36(Suppl 1): 1-22.
40. Than TT, Jo E, Todt D, et al. High environmental stability of hepatitis B virüs and inactivation requirements for chemical biocides. J Infect Dis 2019; 219(7):1044-1048.
41. WHO. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b [erişim 20 Mart 2024].
42. Wong GL, Hui VW, Yip TC, et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther 2022;
56(5): 869-877.
43. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: World Health Organization; 2022.
44. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virüs infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-
2219.
45. Türkiye viral hepatit önlem ve kontrol programı 2018-2023. Ankara: T.C. Sağlık Bakanlığı. [erişim 20 Mart 2024]. https://hsgm.saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Vi-
ral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf
46. Toy M, Önder FO, Wörmann T, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis 2011;
11: 337.
47. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virüs infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; 21: 1020-1026.
48. Furuncuoğlu Y, Sağlam F, Bölükbaş FF, Bölükbaş C, Öztürk R. Seroepidemiology of hepatitis B virüs infection in İstanbul: A 20-year survey. Viral Hepat J 2016; 22: 88-91.
49. Gurol E, Saban C, Oral O, et al. Trends in hepatitis B and hepatitis C virüs among blood donors over 16 years in Turkey. Eur J Epidemiol 2006; 21: 299–305.
50. Bilman FB, Tosun S, Yildiz IE, et al. Prevalence of HBsAg seropositivity during pregnancy and evaluation of vaccination programs: A multicenter study in Turkey. North Clin Istanb 2021; 8(4):
359-364.
51. Tosun S, Erdoğan A, Torun A, et al. Multicenter Study Group. 15-year evaluation of changes in the HBsAg positivity rate in pregnant women in Turkey: the prominent effect of national vac-
cination. East Mediterr Health J 2022; 28(10): 768-775.
52. Serin A, Sahin T, Arikan BT, Emek E, Bozkurt B, Tokat Y. A changing etiologic scenario in liver transplantation: A single-center cohort study from Turkey. Transplant Proc 2019; 51(7): 2416-
2419.
53. Guzelbulut F, Karaogullarindan U, Akkiz H, et al. Characteristics of patients with hepatocellular carcinoma: A multicenter study. Hepatol Forum 2022; 3(3): 71-76.
54. Akarca US, Unsal B, Sezgin O, et al. Study Group OBOKR. Characteristics of newly diagnosed hepatocellular carcinoma patients across Turkey: Prospective multicenter observational 3K
registry study. Turk J Gastroenterol 2021; 32(12): 1019-1028.
55. Akarca US, Baykam N, Güner R, et al. Eliminating viral hepatitis in Turkey: Achievements and challenges. Viral Hepatitis Journal 2022; 28(2): 47-54.
56. Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virüs infection. Nat Rev Immunol 2022; 22(1): 19-32.
57. Seeger C, Mason, WS. Molecular biology of hepatitis B virüs infection. Virology 2015; 479, 672–686.
58. Bénéchet AP, De Simone G, Di Lucia P, et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature 2019; 574: 200–205.
59. Tian Y, Kuo C, Akbari O, Ou JJ. Maternal derived hepatitis B virüs e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission. Immunity 2016; 44,
1204–1214.
60. Guidotti LG, Vecchia CL, Colombo M. Is it time to recommend low- dose aspirin treatment for the prevention of hepatocellular carcinoma? Gastroenterology 2020; 159, 1988–1990.
61. Saitta C, Pollicino T, Raimondo G. Occult hepatitis B virüs infection: An Update. Virüses 2022; 14(7): 1504.
62. Corcorran MA, Kim N. Chronic hepatitis B and HIV coinfection. Top Antivir Med 2023; 31(1): 14-22.
63. Shih YF, Liu CJ. Hepatitis C virüs and hepatitis B virüs co-infection. Virüses 2020; 12(7): 741.
64. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virüs: Advances in prevention, diagnosis, and therapy. Clin Microbiol Rev 2020; 33(2): e00046-19.
65. Mak LY, Hui RW, Fung J, Seto WK, Yuen MF. The role of different viral biomarkers on the management of chronic hepatitis B. Clin Mol Hepatol 2023; 29(2): 263-276.
66. Hadziyannis E. Quantification of HBsAg in serum: characteristics of the assays. OA Hepatol. 2013; 1: 1–6.
67. Shinkai N, Kusumoto S, Murakami S, et al. Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay. Liver Int 2017; 37: 1138–1147.
68. Lunn ER, Hoggarth BJ, Cook WJ. Prolonged hepatitis B surface antigenemia after vaccination. Pediatrics 2000; 105(6): E81.
69. Lazarevic I, Banko A, Miljanovic D, Cupic M. Hepatitis B surface antigen isoforms: Their clinical implications, utilisation in diagnosis, prevention and new antiviral strategies. Pathogens 2024;
13, 46.
70. Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M, Tanaka Y; the PROLIFICA/HBcrAg-RDT Study Group. Rapid point-of-care test for hepatitis B core-related antigen to diagnose high
viral load in resource-limited settings. Clin Gastroenterol Hepatol 2023; 21(7):1943-1946.
71. Fan R, Peng J, Xie Q, et al. Chronic Hepatitis B Study Consortium. Combining hepatitis B virüs RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues
in hepatitis B e antigen-positive patients with chronic hepatitis B. J Infect Dis 2020; 222: 611-618.
72. Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virology 2006;
37: 206-12.
73. Gerlich WH. The enigma of concurrent hepatitis B surface antigen (HBsAg) antibodies to HBsAg. Clin Infect Dis 2007; 44: 1170-1172.
74. Zhang JM, Xu Y, Wang YK, et al. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virüs
infection. Clin Infect Dis 2007; 44: 1161-1169.
75. Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Evaluation of the COBAS Amplicor HBV Monitor assay and comparison with the Ultrasensitive HBV Hybrid Capture 2 assay for quantifi-
cation of hepatitis B virüs DNA. J Clin Microbiol 2005; 43: 596-603.
76. Fryer JF, Rigsby P, Morris CL and the Collaborative Study Group. Collaborative study to evaluate the proposed 5th WHO international standard for hepatitis B virüs (HBV) DNA for nucleic
acid amplification techniques (NAT), 2003 (https://www.who.int/publications/m/item/WHO-BS-2023-2447 [ erişim 20 Mart 2024].
77. Candotti D, Laperche S. Hepatitis B virüs blood screening: Need for reappraisal of blood safety measures? Front Med (Lausanne) 2018; 5: 29.
78. Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 2021; 73: 2167-2179.
79. Shivangi, Mishra MK, Gupta S, Razdan K, Sudan S, Sehgal S. Clinical diagnosis of viral hepatitis: Current status and future strategies. Diagn Microbiol Infect Dis 2024; 108(3): 116151.
80. Sablon E, Shapiro F. Advances in molecular diagnosis of HBV infection and drug resistance. Int J Med Sci 2005; 2: 8-16.
81. Liu T, Sun Q, Gu J, Cen S, Zhang Q. Characterization of the tenofovir resistance-associated mutations in the hepatitis B virüs isolates across genotypes A to D. Antiviral Res 2022; 203: 105348.
82. Cornberg M, Lok AS-F, Terrault NA, Zoulim F. Guidance for design and endpoints of clinical trials in chronic hepatitis B – report from the 2019. EASL-AASLD HBV Treatment Endpoints
Conference. Hepatology 2020; 72(3): 539–557.
83. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virüs infection in the United States: recommendations of the Advisory Committee on immunization practices. MMWR
Recomm Rep 2018; 67(1): 1-31.
HEPATİT DELTA (D) VİRÜSÜ
KAYNAKLAR
1. Rizzetto M. Hepatitis D (Delta). New Microbiol 2022; 45(3): 149-154.
2. Kuhn JH, Babaian A, Bergner LM, et al. ICTV Virüs Taxonomy Profile: Kolmioviridae 2024. J Gen Virol. 2024; 105: 001963.
3. Pearlman B. Hepatitis Delta infection: A clinical review. Semin Liver Dis 2023;43:293-304.
4. Guo H, Li Q, Li C, et al. Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virüs replication and assembly, JHEP Reports 2024; 6:100961.
5. Yurdaydin C, Keskin O, Yurdcu E, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology 2022; 75: 1551-1565.
6. Zhang Z, Urban S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. J Hepatol 2021; 74: 686-699.
7. EASL Clinical Practice Guidelines on hepatitis delta virüs. J Hepatol. 2023; 79: 433-460.
8. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virüs infection: Systematic review and meta-analysis. J Hepatol 2020; 73: 523-532.
9. Lin CC, Lee CC, Lin SH, et al. RNA recombination in hepatitis delta virüs: Identification of a novel naturally occurring recombinant. J Microbiol Immunol Infect 2017; 50: 771–780.
10. Usman Z, Velkov S, Protzer U, Roggendorf M, Frishman D, Karimzadeh H. HDVdb: A Comprehensive Hepatitis D Virüs Database. Virüses. 2020;12(5):538.
11. Demirel A, Uraz S, Deniz Z, et al. Epidemiology of hepatitis D virüs infection in Europe: Is it vanishing? J Viral Hepatit 2024; 31: 120-128.
12. Değertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008; 28: 494-498.
13. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virüs infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; 21: 1020-1026.
14. Toy M, Güler B, Somay K, Gençdal G, Yurdaydin C. Hepatitis delta virüs infection in Turkey: A meta-analysis of prevalence. IJID Reg. 2024; 10: 228-234.
15. Uraz S, Deniz Z, Zerdali EY, et al. The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review. J Viral Hepat 2023; 30: 588-596.
16. Celik I, Karatayli E, Cevik E, et al. Complete genome sequences and phylogenetic analysis of hepatitis delta virüses isolated from nine Turkish patients. Arch Virol 2011; 156: 2215-2220.
17. Le Gal F, Badur S, Hawajri NA, et al. Current hepatitis delta virüs type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different
HDV1 origins. Arch Virol 2012; 157: 647-659.
18. Negro F, Lok AS. Hepatitis D: A review. JAMA. 2023; 330(24): 2376–2387.
19. Sureau C, Deny P. Hepatitis D (Delta) Virüs. In: Howley PM, Knipe DM (eds). Fields Virology, 7th ed. Philadelphia: Lippincott Williams & Wilkins Publishers; 2021.
20. Aslan N, Yurdaydin C, Wiegand J et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 2006; 13(8): 505-14.
21. Chud M, Hanschmann K-M, Bozdayi M, et al. (2013). Collaborative study to establish a World Health Organization international standard for hepatitis D virüs RNA for nucleic acid ampli-
fication technique (NAT)-based assays. World Health Organization. https://iris.who.int/handle/10665/96341 (Erişim tarihi: 23 Nisan 2024)
22. Stelzl E, Ciesek S, Cornberg M, et al. Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: a European multicenter study. J Clin Virol. 2021; 142:
104932.
23. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex) (Erişim tarihi: 23 Nisan 2024)
24. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virüs. Lancet 2011; 378:73-85